Press Release Archive

Our Company March 02, 2021

Johnson & Johnson Statement on Collaboration with Merck

Johnson & Johnson Statement on Collaboration with Merck

Our Company February 28, 2021

Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.

Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.

Our Company February 27, 2021

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use

First Single-Shot Vaccine in Fight Against Global Pandemic

Our Company February 26, 2021

Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

Vote based on totality of scientific evidence provided by the Company including safety and efficacy data

Innovation February 24, 2021

Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA by ViiV Healthcare for Expanded Use of CABENUVA (rilpivirine and cabotegravir) as an HIV Treatment for Use Every Two Months

Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA by ViiV Healthcare for Expanded Use of CABENUVA (rilpivirine and cabotegravir) as an HIV Treatment for Use Every Two Months

If approved, expanded use would offer adults living with HIV an every-two-months long-acting injectable option for maintaining viral suppression

Our Company February 19, 2021

Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate

Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate

Our Company February 16, 2021

Johnson & Johnson Announces Submission of European Conditional Marketing Authorisation Application to the EMA for its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate

Johnson & Johnson Announces Submission of European Conditional Marketing Authorisation Application to the EMA for its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate

Innovation February 08, 2021

Janssen Announces Treatment with ERLEADA^®(apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer

Janssen Announces Treatment with ERLEADA^®(apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer

Final analysis from Phase 3 TITAN study demonstrated ERLEADA^® provided statistically significant overall survival benefit and consistent safety profile in patients with advanced prostate cancer, regardless of extent of disease

Innovation February 08, 2021

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA^®(apalutamide) and ZYTIGA^® (abiraterone acetate) Combination

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA^®(apalutamide) and ZYTIGA^® (abiraterone acetate) Combination

ACIS study meets primary endpoint of improving time to radiographic progression or death in patients with advanced disease

Innovation February 08, 2021

SPRAVATO^® (Esketamine Nasal Spray) Authorised in Europe for the Rapid Reduction of Depressive Symptoms in a Psychiatric Emergency for Patients with Major Depressive Disorder

SPRAVATO^® (Esketamine Nasal Spray) Authorised in Europe for the Rapid Reduction of Depressive Symptoms in a Psychiatric Emergency for Patients with Major Depressive Disorder

· This milestone makes esketamine nasal spray the first N-methyl-D-aspartate (NMDA) antagonist to be approved for patients with Major Depressive Disorder (MDD) in a psychiatric emergency^1–3
· European Commission (EC) authorisation is based on results from two Phase 3 ASPIRE studies, which evaluated the efficacy and safety of esketamine nasal spray used in addition to comprehensive standard of care (SOC)^4–6
· This authorisation marks the second indication for esketamine nasal spray in the European Economic Area (EEA)⁷

Topic

Date

Johnson & Johnson Statement on Collaboration with Merck

Johnson & Johnson Statement on Collaboration with Merck

Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.

Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use

Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee